AB1074 Understanding infusion reactions and their relationship to urate lowering in patients with re...
AB1074 Understanding infusion reactions and their relationship to urate lowering in patients with refractory chronic gout (RCG): Pooled data from pegloticase trials
About this item
Full title
Author / Creator
Baraf, H. , Yood, R. , Sundy, J. , Ottery, F. and Becker, M.
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
More information
Scope and Contents
Contents
Background Pegloticase is a pegylated, mammalian recombinant uricase approved in 2010 in the US for the treatment of chronic gout refractory to conventional therapy. Objectives Gout flares and infusion-related reactions (IRs) were the most commonly reported adverse events (AEs) in recently published Phase 3 pegloticase trials.1 Post-hoc analyses of...
Alternative Titles
Full title
AB1074 Understanding infusion reactions and their relationship to urate lowering in patients with refractory chronic gout (RCG): Pooled data from pegloticase trials
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1777977518
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1777977518
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2012-eular.1073
